Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Effects on Adipose Tissue in Lean and Obese Adults
NCT05634174Phase 1Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mirabegron in obesity and prediabetes (2 arms), sponsored by University of California, San Diego. Primary endpoints: Adrenergic Beta-3 Receptor Gene Expression at 28 days, Adrenergic Beta-3 Receptor Protein Levels at 28 days and 2 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
mirabegron
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on NCT05634174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634174.